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Abstract
Age-related macular degeneration (AMD) is a progressive, degenerative disease of the human retina which in its most 
aggressive form is associated with the formation of macular neovascularization (MNV) and subretinal fibrosis leading 
to irreversible blindness. MNVs contain blood vessels as well as infiltrating immune cells, myofibroblasts, and excessive 
amounts of extracellular matrix proteins such as collagens, fibronectin, and laminin which disrupts retinal function and trig-
gers neurodegeneration. In the mammalian retina, damaged neurons cannot be replaced by tissue regeneration, and subretinal 
MNV and fibrosis persist and thus fuel degeneration and visual loss. This review provides an overview of subretinal fibrosis 
in neovascular AMD, by summarizing its clinical manifestations, exploring the current understanding of the underlying cel-
lular and molecular mechanisms and discussing potential therapeutic approaches to inhibit subretinal fibrosis in the future.
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Introduction
The human macula is a highly specialized region of the 
central retina and indispensable for high-resolution and col-
our vision. Histologically, the retina consists of an inner, 
neurosensory part containing the light-sensitive photo-
receptor cells, neuronal and glial cells, and an outer part 
formed by the retinal pigment epithelium (RPE). The RPE 
is a monolayer of pigmented cells which forms the outer 
blood-retinal barrier, is critically involved in the visual 
process, and separated from the underlying nourishing 
choriocapillaris by a membrane of collagenous and elastic 
fibres, called Bruch’s membrane. The integrity of photore-
ceptors, RPE, Bruch’s membrane, and choriocapillaris as 
a functional unit is crucial for proper human vision and to 
a variable extent impaired in age-related macular degen-
eration (AMD) (Wang et al. 2019). AMD is a progressive, 
degenerative disease of the human macula and one of the 
leading causes of blindness among the elderly population 
in the industrialized world (Flaxman et al. 2017). It is esti-
mated that approximately 288 million people worldwide 
will be diagnosed with AMD by 2040, highlighting the 
significant and ever-growing global health burden of the 
disease (Wong et al. 2014). The exact pathophysiology of 
AMD is still not completely understood. Clinical features of 
the early and intermediate stages of AMD include the pres-
ence of drusen, which are extracellular deposits of lipids, 
proteins, and cellular debris that accumulate between the 
RPE and Bruch’s membrane. While vision can be main-
tained in early and intermediate stages of AMD, most 
severe vision loss occurs in late stages of AMD which are 
classified into two distinctive types: a “dry,” atrophic form 
and a “wet,” neovascular form of AMD (nAMD; Fig. 1). 
The former is characterized by map-like zones of cell 
loss (geographic atrophy) affecting photoreceptors, RPE, 
and choriocapillaris; the latter by disruption of Bruch’s 
membrane and formation of macular neovascularization 
(MNV, previously called choroidal neovascularization, 
CNV). Three MNV subtypes are distinguished according 
to the location of the developing blood vessels. Type 1 
MNV refers to choroidal blood vessels expanding below 
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the RPE (formerly called "occult CNV"), whereas type 2 
MNV is characterized by proliferating choroidal blood ves-
sels breaching Bruch’s membrane and the RPE monolayer 
to spread in the subretinal space (formerly called "classic 
CNV"). Type 3 MNV (formerly called Retinal Angioma-
tous Proliferation, RAP) originate from the retinal vascu-
lature and progress posteriorly into the subretinal space 
(Spaide et al. 2020). In all cases, the newly built irregular 
blood vessels are not tightly sealed and are prone to cause 
leakage and haemorrhage. This disruptive and inflamma-
tory process frequently releases stromal and immune cells 
which trigger transition of the neovascular endothelial bun-
dle to a fibrovascular membrane. While  fibrosis of macu-
lar neovascularization can be beneficial by  limiting exuda-
tion, excessive fibrosis can culminate in subretinal scarring 
with irreversible destruction of photoreceptors, RPE cells, 
and choroidal blood vessels and can thus be responsible 
for the vast majority of severe visual loss in patients with 
nAMD (Ferris et al. 1984). To date, there is no  therapy for 
patients with the atrophic form of AMD  . MNV forma-
tion in neovascular AMD, however, can be suppressed by 
intravitreal application of antibodies against the vascular 
endothelial  growth factor (VEGF) and their introduction 
has significantly advanced the management of nAMD. Nev-
ertheless, significant visual loss (i.e. more than 15 ETDRS 
letters) occurs in about one in four nAMD patients over 
an observation period of 10 years despite continuous anti-
VEGF treatment (Chandra et al. 2020). This phenomenon 
has often been attributed to the formation of subretinal 
fibrosis which occurs in half of the patients with nAMD 
following anti-VEGF therapy (Daniel et al. 2014). The 
pathogenetic mechanisms of subretinal fibrosis, however, 
are poorly understood, and to date, there is no therapy that 
promotes CNV inactivation while preventing excessive 
subretinal fibrosis. In this review, we discuss the clinical 
manifestations of subretinal fibrosis in nAMD, summarize 
our current understanding of the cellular and molecular 
mechanisms of subretinal fibrosis in nAMD and provide 
an overview of potential therapeutic approaches to inhibit 
subretinal fibrosis.
Clinical implications of subretinal fibrosis 
in neovascular AMD
Subretinal fibrosis is the most common natural sequela 
of MNV and causes damage to the photoreceptors, RPE, 
and choriocapillaris, resulting in irreversible loss of cen-
tral vision (Bressler 1988; Wong et al. 2008). Cheung et al. 
reported an increase of subretinal fibrosis in patients with 
treatment-naive nAMD from 13.0 to 37.8% within 1 year 
(Cheung et al. 2019). Histopathological studies show that 
the severity of photoreceptor damage is proportional to the 
size of subretinal fibrosis in AMD eyes (Green and Enger 
1993), supporting the clinical observation that subretinal 
fibrosis is the most important predictor of final visual acu-
ity (Cheung et al. 2019). The risk of eyes with nAMD to 
develop subretinal fibrosis despite ongoing anti-VEGF ther-
apy is reported to be 45% by 2 years (Daniel et al. 2014) 
and 41% by 10 years (Teo et al. 2020). This is of particular 
concern because eyes with subfoveal fibrotic scarring after 
anti-VEGF treatment have the worst prognosis in terms of 
visual acuity after anti-VEGF treatment (Daniel et al. 2014). 
Therefore, alternative therapeutic strategies are needed to 
circumvent the dilemma of inhibiting vessel growth but 
risking the promotion of scar formation at the same time. 
Clinically, subretinal fibrosis can be evaluated by fundus-
copy, fluorescein angiography, and polarization-sensitive 
optical coherence tomography (PS-OCT) and categorized 
into fibrotic and non-fibrotic scars (Roberts et al. 2019). 
While fibrotic scars are characterized as raised clusters of 
white or yellowish tissue that are well-defined in shape and 
appear solid on funduscopy, non-fibrotic scars are typically 
flat, unpigmented lesions with varying amounts of periph-
eral dark pigmentation. Fibrotic and non-fibrotic scars can 
both develop with ongoing anti-VEGF therapy, occurring 
in 24.7% and 20.6% of cases with nAMD after 2 years of 
therapy, respectively (Daniel et al. 2014). However, it is 
unclear whether these clinical subtypes of subretinal fibrosis 
represent pathophysiologically distinct entities or converging 
disease stages.
There are a number of risk factors for the occurrence of 
subretinal fibrosis. In general, eyes are more likely to develop 
subretinal fibrosis during the course of anti-VEGF treatment 
if they have type 2 MNV (classic CNV), blocked fluorescence 
on fluorescein angiography (FA) as an indication of bleeding, 
large basal lesions, increased retinal thickness, foveal sub-
retinal fluid, and subretinal hyperreflective material (SHRM) 
under the foveal centre at baseline (Fig. 2) (Bloch et al. 2013; 
Daniel et al. 2018; Teo et al. 2020). It has been proposed 
Fig. 1  Clinical features of late stages of age-related macular degen-
eration. Funduscopy, infrared (IR, 830  nm), and optical coherence 
tomography (OCT) images of patients with a normal fundus (a–c), 
intermediate AMD (d–f), late stage non-exudative AMD (g–i, geo-
graphic atrophy, GA), and neovascular, exudative AMD (j–l). While 
healthy individuals reveal a homogenous macular appearance with 
a foveal dip in OCT (a–c), patients with intermediate AMD display 
yellowish deposits, called drusen (d, asterisks in f) and pigment epi-
thelium alterations. In GA sharply circumscribed areas of RPE atro-
phy associated with scattered pre-existing drusen can be observed by 
funduscopy, which are associated with loss of retinal pigment epithe-
lium (RPE) cells (g, arrow heads in i) and morphologic alterations of 
the outer retina in the corresponding OCT scan. In nAMD (j–l), sub-
retinal exudation and haemorrhages are seen on fundus photography, 
often accompanied by hyporeflective RPE detachment (arrow in l), 
subretinal fluid, and subretinal hyperreflective material (SHRM, dou-
ble asterisk) on the corresponding OCT scan (l). Scale bar a, b, d, e, 
g, h, j, k = 2 mm; c, f, i, l = 200 µm
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that MNV type 2, which penetrate the RPE layer and grow in 
the subretinal space, are more likely to contain damaged and 
scattered RPE and thus be more likely to progress to fibrosis 
than type 1 MNV, which are usually confined to the space 
beneath the RPE (Ishikawa et al. 2016). Furthermore, several 
studies suggest that intra-retinal or subretinal haemorrhage, 
which can result in blocked fluorescence on FA (Fig. 1), is 
associated with an increased risk of fibrovascular scarring 
(Scupola et al. 1999; Daniel et al. 2018; Teo et al. 2020) sug-
gesting that cellular and molecular components of the blood 
can exaggerate scar formation. The detection of SHRM by 
optical coherence tomography (OCT; Fig. 1) correlates with 
the formation of a retinal scar and is considered a diagnos-
tic biomarker for fibrosis in nAMD (Casalino et al. 2020). 
The exact molecular and cellular composition of SHRM is 
unknown, but it is assumed to be a mixture of fibrovascular 
tissue, haemorrhage, lipids, fibrin, and immune cells, all of 
which show similar reflectivity on OCT. Also, a longer inter-
val between diagnosis and treatment (Bloch et al. 2013) and 
persistent cystoid changes are associated with an even higher 
risk of developing fibrosis compared to persistent diffuse 
subretinal fluid (Gianniou et al. 2015). Subretinal fibrosis in 
patients with nAMD is associated with higher plasma lev-
els of C3a, C4a, and C5a (Lechner et al. 2016); lower serum 
25-hydroxyvitamin D concentrations (Singh et  al. 2013; 
Kim and Park 2018); and a higher percentage of circulating 
CD4 + T-cells as compared to nAMD patients without subreti-
nal fibrosis (Lechner et al. 2015). Interestingly, the incidence 
of scar formation is relatively low in type 3 MNV lesions 
which originate from the retinal vasculature and may therefore 
be more confined to the neurosensory retina without affecting 
the RPE to the same degree as type 1 and type 2 MNV (Chang 
Fig. 2  Multimodal imaging of a patient with neovascular AMD 
showing evidence for macular neovascularisation and submacular 
fibrosis. Funduscopy (a) and fluorescein angiography (b early phase, 
c late phase) at baseline indicate risk factors for the development of 
subretinal fibrosis, including blocked fluorescence. Timecourse of 
infrared-free (d−h) and OCT scans (d′–h′) of the macula showing a 
massive subretinal and sub-RPE bleeding at 3 months, followed by a 
significant formation of subretinal fibrosis and loss of vision to 0.032 
after 3 years despite 13 injections of anti-VEGF-treatment. VA = vis-
ual acuity (decimal). Scale bar a–h = 2 mm; d′–h′ = 200 µm
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et al. 2016; Kim et al. 2018). To date, no genetic and epigentic 
alterations have been found which predispose an individual to 
the formation of subretinal scarring. In particular, no associa-
tion was found between subretinal fibrosis and the common 
single nucleotide polymorphisms (SNPs, complement factor 
H, age-related maculopathy susceptibility 2, complement 
component 3, and toll-like receptor 3) which are known to be 
strongly associated with the development of AMD (Daniel 
et al. 2018).
Basic mechanisms of macular fibrosis
Formation of subretinal fibrosis is based on a still not totally 
understood interplay of multiple cellular and molecular com-
ponents. Similar to other fibrotic diseases, subretinal fibrosis 
in nAMD is the consequence of chronic tissue injury (Friedlander 
2007; Wynn 2007) and consists of partially overlapping 
but functionally distinct temporal phases including cell 
death and inflammation, cell proliferation and tissue replace-
ment, extracellular matrix (ECM) degradation, and tissue 
remodelling. A crucial initial prerequisite for the develop-
ment of MNV is the disruption of Bruch’s membrane, which 
can occur as a result of inflammatory and degenerative pro-
cesses of AMD. Subsequently, MNV arise from the prolif-
eration of choroidal endothelial cells, which can eventually 
penetrate Bruch’s membrane into the subretinal space. These 
newly formed and leaky vessels contribute to the chronic 
damage of the surrounding tissue and lead to an environ-
ment with an abundance of inflammatory mediators. The 
following recruitment, activation, and proliferation of dif-
ferent cell types, such as immune cells and myofibroblasts, 
culminates in excessive ECM deposition and remodelling, 
which is a major feature of fibrotic healing (Wynn 2007). 
Eventually, the neovascular lesion may progress into a fibro-
vascular complex and eventually macular fibrosis, a process 
known as angiofibrotic switch (Roberts et al. 2019). During 
the course of the angiofibrotic switch, apoptosis of retinal 
pigment epithelial cells, endothelial cells, and occasionally 
macrophages occurs, leading to a dominance of the fibrotic 
component within the lesion. In this context, selective apop-
tosis of VEGF-producing cells, such as transdifferentiated 
RPE, appears to further modulate MNV regression (Hinton 
et al. 1998a). It is important to note that although fibrosis 
and the resulting inactivation of pathological CNV may be 
a desirable process, it can often lead to neuroretinal damage 
due to the excessive scar response that accompanies it.
Cellular composition of neovascular fibrosis 
in nAMD
Most of our knowledge of cellular composition of MNV 
lesions is based on histological studies of surgically 
removed neovascular membranes obtained at the time 
before anti-VEGF therapy was available by the mean-
while obsolete surgical treatment of patients with nAMD 
(Fig. 3). Most recently, these investigations were com-
plemented by RNA sequencing and in silico analyses of 
human CNV specimens, providing additional insight into 
the cellular composition (Schlecht et al. 2020). Further 
evidence on the cellular mechanisms underlying CNV 
formation is based on experimental CNV models. Among 
them, the laser-induced CNV mouse model, first described 
by Tobe et al. in 1998 (Tobe et al. 1998), is a widely estab-
lished animal model for neovascular AMD research which 
is frequently used to test anti-fibrotic drugs. In this model, 
targeted laser injury to the RPE and Bruch’s membrane 
induces an acute inflammatory response, recruitment 
of immune cells, and the formation of choroidal neo-
vascularization (Fig. 4). Similar to the human situation, 
a fibrovascular switch occurs in the late stages of this 
model (> 35 days following laser treatment), leading to 
an α-smooth muscle actin (α-SMA) positive fibrotic lesion 
(Ishikawa et al. 2016). Recently, a two-stage laser protocol 
was described in which a second laser burn is applied to 
the neovascular lesion 7 days after initial laser treatment, 
resulting in larger lesions than in the traditional laser-CNV 
model (Little et al. 2020a). Finally, the laser CNV model 
can be expanded by subretinal injection of activated mac-
rophages into the subretinal bleb which forms after laser-
induced rupture of the Bruch’s membrane. This additional 
treatment results in more pronounced subretinal scar for-
mation 7 days after the injection composed of a monoto-
nous, low-cell-density lesion that expresses α-SMA and 
collagens (Jo et al. 2011).
Histological studies of human tissue and pre-clinical 
studies agree that choroidal neovascular membranes are 
composed of different cell types such as RPE cells, vascular 
endothelial cells, glial cells, microglia, macrophages, peri-
cytes, fibroblast-like cells, and myofibroblasts (Little et al. 
2018). In general, fibrotic lesions in the central nervous 
system consist of a fibrotic core, which is closely confined 
by the so-called glial scar. This scar is mainly composed of 
glial cells, such as astrocytes, confining inflammation to the 
core of the lesion and protecting surrounding intact neural 
tissue (Fernández‐Klett and Priller 2014). In the core of 
the lesion, inflammatory cells, such as resident microglia 
and blood-derived macrophages (Grossniklaus et al. 1992, 
1994; Wieghofer et  al. 2021), interact with fibroblasts 
forming a dense fibrotic scar composed of ECM compo-
nents such as osteopontin (secreted-phosphorylated pro-
tein 1, SPP1), fibronectin, collagen, and laminin (Fig. 5). 
The development of a fibrous scar is accompanied by an 
increase in apoptosis and a decrease in cellularity, suggest-
ing that subretinal fibrosis may evolve along with regres-
sion of CNV in nAMD (Hinton et al. 1998b).
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Myofibroblasts and the potential source 
of myofibroblast precursors in subretinal fibrosis
A key element of subretinal fibrosis and expression of ECM 
are myofibroblasts which typically express α-SMA (Schrimpf 
and Duffield 2011; Little et al. 2018). Ongoing presence and 
persistent stimulation of myofibroblasts are associated with 
excessive ECM deposition which can ultimately result in organ 
dysfunction (Hinz 2016; Darby et al. 2016). As myofibroblasts 
are absent in the healthy macula, it is plausible to assume that in 
nAMD, they develop from myofibroblast precursor cells (Little 
et al. 2018; Shu et al. 2020). Multiple cell types can contribute 
to macular fibrosis in nAMD through their activation or trans-
differentiation into myofibroblasts. The origin of myofibroblasts 
in human nAMD is difficult to decipher as respective markers 
are lost in the transdifferentiation process. Among the potential 
candidates, RPE cells undergoing epithelial-mesenchymal 
transition (EMT) are considered a major source of myofibroblasts 
(Ishikawa et al. 2016; Little et al. 2018; Shu et al. 2020). In the 
healthy eye, RPE cells exhibit a mature epithelial phenotype 
and are unable to proliferate due to efficient cell–cell contact 
inhibition mediated by homotypic adhesion of cadherins to 
adjacent cells (Yang et al. 2018). Upon loss of cell–cell contact 
and under the influence of growth factors such as TGFβ, RPE 
cells lose their epithelial phenotype leading to decreased 
expression of epithelial markers such as cadherins and zonula 
occludens 1 (ZO-1) and a disruption of the barrier function 
of tight junctions. At the same time, an increased expression 
of mesenchymal markers such as N-cadherin, vimentin, and 
α-SMA can be observed. Thus, RPE cells can disassociate, gain 
the ability to proliferate, and undergo EMT contributing to ECM 
deposition and MNV disease progression (for a detailed review 
see (Zhou et al. 2020)). In addition, Müller cells, which belong to 
the glial cells of the retina, can differentiate into myofibroblasts. 
Porcine Müller cells showed an increased expression of α-SMA 
under routine cell culture conditions, suggesting that Müller 
Fig. 3  Cellular composition of a human CNV membrane. a–c Hema-
toxylin and eosin staining of a surgically excised human fibrovascular 
membrane showing an overview of the resected tissue (a), a fibrotic 
area with low cell density (b) next to an area with increased cell den-
sity, and several vessels (some indicated by arrow heads, c). The cel-
lular components of a human CNV membrane include CD68 + (d) 
and IBA1 + (e, f) macrophages/microglia as well as vascular endothe-
lial cells, pericytes, fibroblast-like cells, and myofibroblasts (not 
shown). Iba1 positive microglia and macrophages contribute to 
ECM formation by expressing e.g. SPP1 (arrow heads, f). Scale bar: 
a = 1 mm; b, c = 75 μm; d, e = 50 μm; f = 20 μm
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cells can contribute to the myofibroblast pool (Guidry 1996). 
Transdifferentiation of endothelial cells into myofibroblast-like 
cells is considered a further origin of myofibroblasts in nAMD 
(Shu et al. 2020) and was described as endothelial-mesenchymal 
transition (EndMT). Little et al. (2018) also assumed circulating 
fibrocytes as myofibroblast precursors as they have been 
identified in choroidal neovascular membranes (Grossniklaus 
et al. 1994) and have the potential to differentiate into fibroblasts. 
This is of particular interest as recent studies in the brain suggest 
that the majority of fibrotic scarring originates from proliferative 
CNS fibroblasts that express interferon-gamma pathway genes 
and collagen1α1 among others (Soderblom et al. 2013; Dorrier 
et al. 2021). Pericytes have been shown to be myofibroblast 
precursors in the kidney (Schrimpf and Duffield 2011) and 
could represent another myofibroblast source in nAMD. Luo 
et al. identified choroidal pericytes as a source of myofibroblasts 
in a model of laser-induced CNV and showed that choroidal 
pericytes play a role in the formation of subretinal fibrosis by 
expressing ECM components (Luo et al. 2018). Finally, myeloid 
cells such as macrophages transdifferentiate into myofibroblasts 
in experimental fibrotic kidney disease (Meng et al. 2016) and 
express α-SMA under TGFβ induction in vitro (Little et al. 
Fig. 4  Cellular composition of experimental murine CNV/scar mem-
branes. (a–c) In vivo imaging of the murine fundus 14 days following 
laser application (a) and the corresponding fluorescein angiography 
(FA, b) showing leakage at sites of CNV membranes (circle) and an 
accumulation of Cx3cr1-GFP + myeloid cells at sites of CNV (c). 
D) Immunohistochemistry staining of an experimental murine CNV 
lesion showing vascular endothelial cells (Col4, d), myeloid cells 
(Cx3cr1-GFP + , d′) the ECM component FN-1 (d″) and a merged 
image (d‴).e) Higher magnification of D‴ demonstrates that myeloid 
cells contribute to ECM formation by expressing FN-1. Scale bar: 
a–d = 100 μm; e = 10 μm
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2018). Recent preclinical evidence by Little and colleagues 
shows that F4/80 + myeloid cells express α-SMA indicating that 
myeloid cells can undergo TGF-β-induced and C3a-dependent 
macrophage-to-myofibroblast transition (MMT) at sites of MNV. 
In line with these findings, approximately 20% of infiltrating 
Iba-1 + myeloid cells in human MNV were reported to be 
immunoreactive for α-SMA, suggesting that MMT is present in 
macular fibrosis secondary to nAMD (Little et al. 2020b) (Fig. 5).
Immune response
Inflammatory responses, particularly infiltration and 
activation of cells of the innate immune system, are 
critically involved in the development and progression 
of nAMD (Chen and Xu 2015). In particular myeloid 
cells, such as blood-derived macrophages and resident 
retinal microglia, can sense exogenous and endogenous 
danger-associated molecular patterns, migrate to sites 
of CNV, and drive secondary injury through a vicious 
neuroinflammatory cycle (Wieghofer et  al. 2021). In 
addition to the functions already mentioned, myeloid cells 
stimulate proliferation and differentiation of stromal cells 
by producing pro-inflammatory and pro-fibrotic mediators 
and contribute to further recruitment of immune cells by 
secreting chemoattractants. The origin of myeloid cells 
during CNV formation has long been a subject of debate. 
Recent evidence suggests that retinal MG constitute the 
major myeloid cell population in the diseased retina and 
RPE with lower numbers of recruited monocytes during 
Fig. 5  Cellular and molecular interactions in macular scar forma-
tion in nAMD. The fibrotic scar is characterized by the deposi-
tion of extracellular matrix molecules, such as collagens, laminins, 
fibronectin and osteopontin (secreted phosphoprotein 1, SPP1), which 
are otherwise scarcely expressed in the retina and subretinal space. 
These molecules are mostly generated by myofibroblasts, which 
are normally absent from the retinal and choroidal parenchyma. 
The scar stroma cells (myofibroblasts) may originate from endothe-
lial cells, RPE cells, Müller cells, choroidal fibroblast, pericytes, or 
innate immune cells. Blood‐borne macrophages, resident microglia, 
and RPE cells contribute to the proliferation and differentiation of 
stromal cells by producing profibrotic mediators, and they are also 
involved in eventual fibrous scar resolution. Conversely, stromal cells 
modulate neuroinflammation by producing cytokines, chemokines, 
and adhesion molecules. CNV = choroidal neovascularization, PR 
OS = photoreceptor outer segments, RPE = retinal pigmented epithe-
lium, TGFβ = transforming growth factor β, PDGF = platelet-derived 
growth factor, CTGF = connective tissue growth factor, FGF2 = con-
nective tissue growth factor, VEGF = vascular endothelial growth fac-
tor
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experimental CNV and GA (Ma et al. 2017; Wieghofer 
et  al. 2021). Depending on the temporal phase of the 
disease, myeloid cells may exert a dual role with damaging 
and protective properties. Myeloid cells are involved in 
immune cell recruitment and secondary tissue damage with 
resultant scarring in the initial stage. However, they can also 
adopt an anti-inflammatory phenotype that promotes tissue 
remodelling and repair through removal of cellular and 
myelin debris, degradation of scar tissue, and production 
of neurotrophic factors in later stages (D’Ambrosi and 
Apolloni 2020). For example, resident microglia contribute 
to the formation of the gliotic barrier by expressing the 
matricellullar protein Osteopontin (OPN, gene name SPP1) 
at sites of human and murine CNV (Schlecht et al. 2020, 
2021). OPN is expressed by myeloid cells after ischemic or 
traumatic brain injury and contributes to the formation of 
the gliotic barrier by binding to α(v)β3-integrin on astrocytes 
(Ellison et al. 1998). In the core of the lesion, microglia 
may contribute to the pro-inflammatory milieu, e.g. by 
expressing cytokines such as IL-1β, IL-6, and tumour 
necrosis factor (TNF)-α, which can exacerbate fibrosis in 
the CNS (Schrimpf and Duffield 2011). Recent evidence 
suggests that IL-6, expressed by activated microglia, is 
a crucial mediator promoting subretinal fibrosis and that 
targeting IL-6 and the corresponding signalling pathway 
would be an attractive therapeutic approach not only in 
macular neovascularization, but also in subretinal fibrosis 
(Sato et al. 2018a). In addition, the presence of activated 
macrophages, which secrete anti-inflammatory and pro-
fibrotic factors such as TGF-β1 and Platelet-derived growth 
factor (PDGF), has been associated with the accumulation 
of myofibroblasts and the deposition of fibrillar ECM in 
the brain (Murray and Wynn 2011). In humans, TGFBR1 
expression could be traced back to retinal microglia 
further corroborating an active role of myeloid cells in 
this complex interplay of different cell types (Menon 
et  al. 2019). Activated microglia, which secrete pro-
inflammatory cytokines, also induce the so-called “A1” 
reactive astrocytes in neurodegenerative brain diseases 
such as Alzheimer’s disease (AD), which are no longer 
able to support neuronal cell survival and differentiation 
and instead promote neuronal and oligodendrocyte death 
(Liddelow et al. 2017). On the other hand, macrophages 
are also crucial for the resolution of fibrosis (Duffield et al. 
2005), which in the brain is associated with the expression 
of IL-13 receptor α2, IL-10 and arginase (Wilson et al. 
2007; Pesce et al. 2009). Therefore, a simple categorization 
of the function of myeloid cells is impossible, as their 
responses are characterized by deleterious as well as 
protective properties, which are closely interrelated and 
mutually dependent. Recent evidence suggests that disease-
specific microglia subpopulations with distinct molecular 
signatures accumulate at sites of experimental murine 
CNV (Wieghofer et al. 2021). The exact temporo-spatial 
function of these microglial subpopulations during CNV 
development is still enigmatic and will be the subject of 
further studies that may provide the basis for targeted MG 
modulating therapy in patients with nAMD.
Growth factors
The aforementioned cells interact and communicate via the 
secretion of growth factors that control cell recruitment, 
proliferation, and death in nAMD. Numerous cytokines and 
chemoattractants contribute to this process. For a detailed 
overview, the reader is referred to the excellent reviews by 
(Chen and Xu 2015; Little et al. 2020b).
TGFβ
Transforming growth factor beta (TGFβ) is a central pro-
fibrotic mediator and a master regulator inducing mesenchy-
mal transition of a variety of cells, such as epithelial cells 
(Xu et al. 2009), endothelial cells (Pardali et al. 2017), and 
macrophages (Little et al. 2018). TGF-β was found to be 
expressed in surgically removed CNV tissue (Amin et al. 
1994) and in the vitreous of patients with retinal fibrosis 
(Connor et al. 1989). In the latter, TGF-β2 was found to 
be more highly expressed than the other TGF-β isoforms 
and its expression correlated with scar severity (Connor 
et al. 1989; Pfeffer et al. 1994). TGF-β2 induces epithelial 
mesenchymal transition of RPE cells predominately by the 
SMAD3 signalling pathway (Saika et al. 2004) which plays 
a prominent role in the activation of TGF-β-dependent gene 
targets, such as plasminogen activator inhibitor-1 (PAI-
1) and various collagens, including COL1A1, COL1A2, 
COL3A1, COL5A2, COL6A1, and COL6A3 (Flanders 
2004). Moreover, TGF-β2 signalling can induce TGF-β1, 
PDGF, and CTGF expression suggesting that TGF-β2 could 
orchestrate the secondary effects of these other mediators 
on EMT and fibrosis (Saika et al. 2004). Levels of active 
TGF-β1 and TGF-β2, but not TGF-β3, were strongly 
upregulated in mice with subretinal fibrosis in comparison 
to control mice, and intraperitoneal injection of TGF-β-
neutralizing antibodies resulted in the inhibition of sub-
retinal fibrosis (Zhang and Liu 2012). Furthermore, retinoic 
acid receptor-γ agonist was shown to attenuate TGF-β2-
induced EMT in vitro and to suppress experimental sub-
retinal fibrosis in mice (Kimura et al. 2015). Similarly, the 
inhibition of the transcriptional regulator myocardin-related 
transcription factor A (MRTFA) leads to reduced expres-
sion of EMT markers induced by TGFβ in human RPE cells 
and is effective in inhibiting subretinal fibrosis development 
in vivo. Interestingly, MRTFA did not affect CNV forma-
tion indicating that it might directly target subretinal fibrosis 
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(Kobayashi et al. 2019). Therefore, inhibition of the TGF-β 
pathway has been advocated as an additional treatment for 
neovascular AMD. However, further efforts are necessary 
to clarify its controversial and cell-dependent involvement 
in nAMD pathogenesis (Tosi et al. 2018).
CTGF
Connective tissue growth factor (CTGF) plays a role in 
various biological processes and is considered an important 
regulator of the molecular mechanisms that take place in 
the process from wound healing to tissue fibrosis (Ramazani 
et al. 2018). CTGF can be detected in MNV by immunohis-
tochemistry and stained more intense in MNV classified as 
moderate or extensive fibrosis indicating that CTGF may 
promote ECM deposition (Watanabe et al. 2005). Preclini-
cal studies summarized by Ramazani et al. indicated that 
targeting CTGF may serve as a potential therapeutic target 
to inhibit fibrotic processes (Ramazani et al. 2018). Using 
the laser-induced CNV-model Daftarian et al. found that 
inhibition of  CTGF resulted in significant reduction of sub-
retinal fibrosis (Daftarian et al. 2019) suggesting a role for 
CTGF in context of nAMD and fibrosis.
FGF
The fibroblast growth factor (FGF) family comprises 23 
members with 22 of them found in humans (Yun et  al. 
2010). FGF2, also known as basic FGF, has been identified 
in human choroidal neovascular membranes (Frank et al. 
1996). FGF2 stimulated TGFβ-induced EMT of RPE cells. 
The inhibition of FGF2 was associated with decreased CNV 
and subretinal fibrosis in a mouse laser-induced CNV model 
(Matsuda et al. 2019).
PDGF
The platelet-derived growth factor is a well-established 
central mediator of vascular homeostasis and pericyte 
differentiation and a key player in the regulation of fibrotic 
processes throughout the human body (Andrae et al. 2008). 
Thus, PDGF represents an attractive target to reduce CNV 
formation and concomitant subretinal fibrosis (Erber et al. 
2004). In preclinical models, anti-PDGF therapy detached 
pericytes from underlying endothelial cells during ocular 
neovascularisation (Mitchell et al. 2008), making endothelial 
cell-lined neovascular tubes highly susceptible to the effects 
of anti-VEGF therapy (Erber et al. 2004; Jo et al. 2006). 
Further studies suggest that pericytes and PDGF play a key 
role in forming a scaffold for endothelial cells during the 
early stages of experimental CNV formation (Strittmatter 
et al. 2016) and that PDGF is a potent chemoattractant 
for immune, RPE, and glial cells (Andrae et al. 2008). In 
a laser-induced CNV mouse model suppression of PDGF 
signalling by blocking one of its receptors, the platelet-
derived growth factor receptor β (PDGFRβ) resulted in 
attenuated CNV formation and reduced subretinal fibrosis 
(Liu et al. 2020) thus paving the way for evaluating anti-
PDGF therapy in clinical trials.
Extracellular matrix
Histological studies showed that choroidal neovascular 
membranes are composed of ECM components such as col-
lagen, fibronectin, and laminin (Grossniklaus and Green 
1998; Grossniklaus et al. 1994; Hinton et al. 1998a, b; Lopez 
et al. 1996). Recent RNA sequencing analysis of human 
CNV membranes furthermore revealed increased COL6A1, 
COL3A1, SPP1, and SPARC expression in human CNV 
membranes compared to control tissue (Schlecht et al. 2020). 
Furthermore, periostin, which is a ligand for several integ-
rins and thus supports epithelial cell adhesion and migration, 
is an important ECM component in human MNV (Yoshida 
et al. 2019) and has been discussed as a possible anti-fibrotic 
therapeutic target (Nakama et al. 2015).
Potential therapeutic targets
To date, there is no anti-fibrotic treatment available to reduce 
subretinal scarring in patients with nAMD. Clinical trials 
showed that anti-VEGF monotherapy cannot prevent the 
development of macular fibrosis (Bloch et al. 2013; Roberts 
et al. 2019), although it was suggested that timely initiation 
of therapy may be beneficial in preventing fibrosis (Bloch 
et al. 2013). This could be explained mainly by its inhibitory 
effect on angiogenesis and vasopermeability, which reduces 
the infiltration of immune cells and thus the extent of the 
inflammatory response. Since the occurrence of fibrosis is 
the most important predictor of final visual acuity (Cheung 
et al. 2019), recent efforts have been made to target fibro-
blast proliferation in nAMD to limit scarring. As discussed 
above, there is a growing list of molecular mediators and 
pathways that could be exploited in the development of novel 
anti-fibrotic drugs. These include cytokine, chemokine and 
toll-like receptor (TLR) antagonists, angiogenesis inhibitors, 
TGFβ signalling modifiers, immune cell modulators, or stem/
progenitor cell transplantation strategies, to name just a few 
(see Table 1). In light of the encouraging pre-clinical data on 
anti-PDGF therapy to suppress fibrosis (see above), recent 
clinical trials have assessed the efficacy of a combined anti-
PDGF and anti-VEGF treatment compared with anti-VEGF 
monotherapy in patients with nAMD (Jaffe et al. 2016, 2017). 
The rationale for targeting both molecules was to exploit the 
anti-fibrotic properties of anti-PDGF and to improve the anti-
VEGF efficiency by stripping of pericytes from newly formed 
vessels thus exposing them to anti-angiogenic therapy.
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In 2017, Jaffe et al. reported that anti-PDGF and anti-
VEGF combination therapy was more effective than anti-
VEGF monotherapy in improving visual acuity and in limit-
ing the development and progression of fibrosis in a Phase IIb 
randomized clinical trial (Jaffe et al. 2017). In eyes with visual 
acuity loss at 24 weeks post treatment, anti-PDGF and anti-
VEGF combination therapy was associated with significantly 
less subretinal fibrosis and less subretinal fibrosis progression 
(10% and 27%, respectively), compared with eyes receiving 
anti-VEGF monotherapy alone (51% and 54%, respectively). 
These encouraging results paved the way for a large phase 
III clinical trial (NCT01944839), which, however, failed to 
replicate the success of the phase 2b trial and did not meet 
the primary endpoint of mean change in visual acuity at 
12 months (Hussain and Ciulla 2017). Detailed results of this 
study, especially on fibrosis formation, have not been pub-
lished to our knowledge.
Conclusions
Subretinal fibrosis is the most common natural sequela of 
macular neovascularization and develops despite successful 
anti-VEGF therapy. Current evidence suggests that subretinal 
fibrosis and its ECM components are produced mainly by 
activated myofibroblasts that transdifferentiate from RPE, 
pericytes, endothelial, glial, and immune cells, leading to a 
secondary response involving the innate immune system. The 
biological function of subretinal fibrotic material deposition 
most likely is to limit the spread of tissue injury, but the 
associated prolonged and massive reaction eventually leads to 
irreversible vision loss and impedes tissue regeneration. While 
wound healing is to some extent a useful process in nAMD, 
it would be therapeutically helpful to modulate scarring, 
resolve scar tissue and thus improve photoreceptor survival 
by manipulating for example, myofibroblasts derived from 
stroma and immune cells. Although the targeted inhibition 
of single factors, such as PDGF, has shown first promising 
clinical results, the pathophysiology of multiple signalling 
pathways in scar formation seems to be too complex to 
achieve relevant clinical success by inhibiting a single 
factor alone. Nevertheless, an increasing understanding of 
the involved ECM molecules may lead to the identification 
of new potent anti-fibrotic therapeutic targets that can be 
inhibited by intravitreal drug administration. Furthermore, the 
investigation of ECM components and scarring mechanisms 
in organisms capable of CNS regeneration, such as the 
zebrafish, may lead to the identification of pro-repair targets. 
For example, the Wnt/β-catenin signalling controls the 
differential regulation of collagen XII within the scar matrix 
and thus contributes to the pro-regenerative phenotype 
in zebrafish. These findings imply that the Wnt/β-catenin 
Table 1  Summary of selected, relevant anti-fibrotic drugs for the treatment of experimental subretinal fibrosis. Alphabetical order. No claim to 
completeness. CNV: choroidal neovascularization, OIR: oxygen induced retinopathy, RPE: retinal pigment epithelium
Therapy Model Route of administration Reference
Ac-EEED (actin blockage) Mouse, laser CNV intravitreal Caballero et al. (2011)
Adrenomedullin Mouse laser CNV intravitreal Tanaka et al. (2020)
Cavtratin (caveolin-1) Mouse laser CNV intravitreal Shimizu et al. (2020)
Connective tissue growth factor antagonism Rat laser CNV intravitreal Daftarian et al. (2019)
Cyclooxygenase 2 antagonism (NS-398) Mouse laser CNV intraperitoneal Zhang et al. (2016)
Doxycyclin Mouse laser CNV intraperitoneal Peng et al. (2018)
Fibroblast growth factor 2 antagonism (RBM-007) Mouse and rat laser CNV intravitreal Matsuda et al. (2019)
Heat shock protein 70 Mouse subretinal fibrosis intravitreal Yang et al. (2013)
Interleukin 6 antagonism Mouse subretinal fibrosis intravitreal Sato et al. (2018b)
Interleukin 6 receptor antagonism Mouse subretinal fibrosis intravitreal Sato et al. (2018b)
Mouse subretinal fibrosis intraperitoneal Cui et al. (2014)
Lysyl oxidase and lysyl oxidase-like 2 antagonism Mouse laser CNV intraperitoneal Van Bergen et al. (2015)
Myocardin-related transcription factor A inhibitor Mouse laser CNV intravitreal Kobayashi et al. (2019)
Periostin antagonism Mouse laser CNV intravitreal Nakama et al. (2015)
Phosphatidylinositol-3-kinase inhibitor (3-MA) Mouse laser CNV intraperitoneal Bo et al. (2020)
Platelet Activating Factor Receptor antagonism Mouse laser CNV intraperitoneal Zhang et al. (2013)
Platelet derived growth factor receptor-β antagonism Mouse laser CNV intravitreal Liu et al. (2020)
(Pro) Renin receptor antagonism Mouse laser CNV intravitreal Liu et al. (2019)
Rho kinase inhibitor (AMA0428) Mouse laser CNV intravitreal Hollanders et al. (2015)
Sphingosine-1-phosphate antagonism Mouse laser CNV intravitreal Caballero et al. (2011)
Transforming growth factor beta antagonism Mouse subretinal fibrosis intraperitoneal Zhang and Liu (2012)
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pathway and Collagen XII may also be targets for extracellular 
matrix manipulations in neovascular AMD (Wehner 
et al. 2017). Finally, broader therapeutic strategies aimed at 
inhibiting mesenchymal transdifferentiation or modulating 
fibroblasts and active glial and immune cells could limit 
the associated chronic inflammation and thus effectively 
reduce fibrosis. However, there are challenging hurdles that 
need to be overcome before treatment can be translated into 
clinical practice. Although considerable progress has been 
made in recent years, our understanding of the molecular and 
cellular mechanisms needs to be further enhanced. Continued 
scientific studies on human CNV membranes exploiting 
single-cell proteomics, single-cell RNA sequencing, and 
systems biology approaches will be necessary to define the 
cell types involved and the signalling pathways activated in 
them. Single-cell RNA sequencing approaches, for example, 
can reveal the mRNA expression profile of complex and rare 
cell populations in MNV, uncover regulatory relationships 
between genes, and track the trajectories of distinct cell 
lineages in disease progression (Hwang et al. 2018). These 
studies can be complemented by proteomic studies, e.g. by 
mass spectrometry, on MNV tissues, which will allow further 
delineation of the mechanisms involved in the diseases and 
identification of new biomarkers or drug targets. In addition, 
systems biology approaches will be valuable to integrate 
genomic, transcriptomic, proteomic, pharmacological, and 
clinical data from patients with nAMD into mathematical 
models that may predict disease onset and progression, 
identify biomarkers, and eventually unravel disease-causing 
mechanisms (Handa et  al. 2019). However, as human 
MNV membranes are no longer surgically extracted in 
clinical practice, these single cell analyses will be difficult 
to accomplish. Therefore, further efforts should be made to 
establish novel and optimised animal models that resemble 
the human situation and the clinical picture of AMD even 
more closely and may thus be available for the preclinical 
evaluation of potential future therapeutic approaches. Another 
difficult obstacle will be the design of effective clinical 
trials with well-defined clinical endpoints. For this purpose, 
predictive serum markers, improved imaging techniques or 
other clinical features that can serve to accurately monitor 
the course of subretinal fibrosis in a quantitative manner are 
needed. In addition, the search for genetic factors, such as 
single nucleotide polymorphisms (SNPs), should continue to 
determine the individual relative risk of developing fibrosis. 
The identification of a predictive genetic signature associated 
with a high risk of developing subretinal fibrosis would be 
crucial to detect fibrosis processes early and apply an anti-
fibrotic therapy specifically tailored to the patient. Since the 
incidence of AMD and thus the number of patients suffering 
from subretinal fibrosis continues to increase, there will be a 
high and increasing need in anti-fibrotic drugs that are both 
safe and effective.
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